RxDoctor Payments Data

Tammy Leong, MD

Internal Medicine · Birmingham, ALNPI 1477615425

Payments from drug & device makers

$4,106in general payments, 2019–2025

Across 279 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$546
  • Abbott$478
  • AbbVie$465
  • Amarin Pharma, Inc.$180
  • Bayer$136
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,106100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,106 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$60,138
Medicare patients
223
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide131$148,220
OzempicSemaglutide68$78,825
EliquisApixaban77$69,194
JardianceEmpagliflozin77$53,820
JanuviaSitagliptin Phosphate44$41,716
RybelsusSemaglutide18$25,957
TrulicityDulaglutide21$23,417
Breo ElliptaFluticasone/Vilanterol33$17,097
WegovySemaglutide13$16,415
MyrbetriqMirabegron15$14,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,437
Lantus SolostarInsulin Glargine,hum.Rec.Anlog86$11,887
XareltoRivaroxaban14$11,136
LinzessLinaclotide11$5,988
Risedronate Sodium33$5,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$42$171,637152 claims
Novo NordiskOzempic, Rybelsus, Wegovy$1,289$121,19899 claims
PfizerEliquis$546$69,19477 claims
Boehringer IngelheimJardiance$32$53,82077 claims
GSKBreo Ellipta, Trelegy Ellipta$69$29,53450 claims
Astellas Pharma US IncMyrbetriq$94$14,48215 claims
Johnson & JohnsonXarelto$123$11,13614 claims
AbbVieLinzess, Synthroid$465$10,82075 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →